FOXP3 and neoplasm: Immunosuppressive FOXP3-positive Tregs are present in the tumor microenvironment (TME) in numerous solid and hematologic malignancies (7) and have been linked to poor prognosis (12) and a lack of response to PD-(L)1 checkpoint inhibition (13, 14).